Policy & Regulation
Arcturus Therapeutics and Thermo Fisher enter strategic collaboration on ARCT-032 development
2 July 2026 - Messenger RNA medicines company Arcturus Therapeutics Holdings Inc (Nasdaq:ARCT) announced on Thursday that it has entered into a strategic collaboration with Thermo Fisher Scientific In...
Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer
2 July 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), on Thursday reported positive Phase III results from the Krascendo 1 trial evaluating investig...
Neurocrine Biosciences initiates crinecerfont Phase 2 study in young children with classic CAH
2 July 2026 - Biopharmaceutical company Neurocrine Biosciences Inc (Nasdaq:NBIX) announced on Wednesday the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfo...
Abbisko Therapeutics and AstraZeneca collaborate to conduct combination clinical trial for NSCLC
2 July 2026 - Chinese biopharmaceutical company Abbisko Therapeutics Co Ltd (HKEX:02256) announced on Wednesday that it has entered into a strategic collaboration agreement with biopharmaceutical comp...
Cumberland Pharmaceuticals sharpens focus on rare disease pipeline with USD100m sale of branded US business to Apotex
1 July 2026 - US biopharmaceutical company Cumberland Pharmaceuticals Inc (Nasdaq: CPIX) announced on Wednesday that it has completed a USD100m transaction with Apotex, a subsidiary of Canadian-based ...
Ipsen to acquire Memo Therapeutics to expand rare disease portfolio
1 July 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Wednesday that it has agreed to acquire all outstanding shares of Memo Therapeutics AG in a transacti...